Baker Bros. Advisors Adds $11M in Evommune, Inc. ($EVMN)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors acquired a new position in Evommune, Inc. ($EVMN), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 847,390 shares of Evommune, Inc.. Baker Bros. Advisors's holdings in Evommune, Inc. were worth $11.26 million as of its most recent filing.
Evommune, Inc. Stock Up 0.5%
Shares of Evommune, Inc. ($EVMN) traded around $13.29 on Sunday, up 0.5% for the day.
Evommune, Inc. Earnings
Analysts Set New Price Targets
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Get Evommune, Inc. alerts
New 13F filings, insider trades, and analyst moves on $EVMN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.